KNTPF.US Kintor Pharmaceutical Limited

Healthcare Biotechnology USA Stocks
0.1567 USD
Close of Nov 15, 2026
0.1542 0.5708
Market cap
USD 76.6M
P/E
-
P/B
4.68x
ROE
-273.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is KNTPF.US undervalued?

Graham number

The Graham number of Kintor Pharmaceutical Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kintor Pharmaceutical Limited fundamental analysis

No fundamental analysis for Kintor Pharmaceutical Limited yet.

Kintor Pharmaceutical Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing AL…

Full company profile